AMS (American Shared Hospital Services) Q2 2026: Direct Patient Services Revenue Surges 40%, Highlighting Diversified Growth Path
American Shared Hospital Services demonstrated robust top-line growth driven by its expanding direct patient services and international operations, underscoring the payoff from strategic investments in advanced radiation therapy technologies. Operational momentum is further supported by strong cash flow generation and enhanced liquidity following recent financing activities. The company’s ongoing efforts to optimize utilization and expand its treatment footprint position it well for sustainable long-term value creation despite near-term balance sheet challenges.
Summary
- Strategic Diversification Strength: AMS is successfully transitioning from equipment leasing to a multi-channel radiation oncology platform.
- Operational Execution Focus: Patient volume growth and utilization improvements are driving revenue across domestic and international centers.
- Liquidity and Flexibility Enhanced: Financing amendments and subordinated capital injection provide runway for strategic initiatives.
Business Overview
American Shared Hospital Services (AMS) operates as a provider of stereotactic radiosurgery equipment and advanced radiation therapy services, catering primarily to cancer treatment centers and hospital networks across North and South America. The company’s revenue streams are principally derived from two segments: Direct Patient Services, which includes operations of radiation oncology centers providing treatments, and Medical Equipment Leasing, encompassing leasing of Gamma Knife and Proton Beam Radiation Therapy (PBRT) systems. AMS’s business model leverages partnerships with health systems to share capital investment and operational profits, aiming to expand patient access and treatment capabilities.
Performance Analysis
For the second quarter of 2026, AMS reported a 19% year-over-year revenue increase to $8.4 million, driven primarily by a 40% surge in its Direct Patient Services segment to $4.9 million. This growth was fueled by higher procedure volumes at the Rhode Island radiation therapy centers and international facilities in Peru and Puebla, Mexico. The Proton Beam Radiation Therapy segment also contributed meaningfully, with revenue rising 22% to $2.3 million, reflecting a 10% increase in treatment fractions and improved reimbursement rates. Meanwhile, international Gamma Knife operations benefited from the Esprit system upgrade in Peru, boosting procedure volumes and revenue by 56% in the first half of 2026 compared to the prior year.
Despite the revenue growth, gross margin declined slightly year-over-year to $1.4 million in Q2 but improved sequentially from Q1 2026, reflecting the different cost structures between leasing and direct patient services and ongoing operational scaling. Adjusted EBITDA decreased to $1.3 million from $1.7 million in the prior year quarter, impacted by increased legal fees related to credit agreement amendments and a $909,000 allowance for credit losses on accounts receivable predating May 2025. Operating cash flow remained strong, generating $4.4 million in the first half of 2026, supporting scheduled debt repayments and cash reserves that nearly doubled to $6.8 million by quarter-end.
- Revenue Expansion Across Segments: Direct Patient Services and PBRT led revenue growth, highlighting successful diversification.
- Margin and Expense Dynamics: Gross margin pressures reflect mix shifts and one-time legal and credit loss expenses.
- Cash Flow Resilience: Operating cash flow generation supports debt reduction and liquidity enhancement.
AMS’s financial performance underscores the benefits of its strategic shift toward recurring revenue streams from patient services and international market expansion, offsetting legacy equipment leasing softness. The company’s emphasis on improving utilization rates and operational efficiency is beginning to translate into stronger profitability potential.
Executive Commentary
"Our second quarter results demonstrate the strength of our diversified radiation oncology platform... These results underscore the benefits of the strategic investments we have made over the past several years to expand our treatment capabilities and geographic footprint."
Craig Tagawa, Interim Chief Executive Officer
"The fundamentals of our business remain strong. Demand for advanced radiation therapy continues to grow, and our portfolio of Gamma Knife, Proton Beam Radiation Therapy and radiation oncology centers positions AMS to participate across multiple areas of cancer treatment."
Ray Stachowiak, Executive Chairman
Strategic Positioning
1. Diversification from Equipment Leasing to Direct Patient Services
AMS has strategically shifted its revenue base from primarily equipment leasing toward direct patient care operations, which now represent an increasingly significant portion of total revenue. This transition enhances recurring revenue stability and operational control over procedure volumes, a critical driver of profitability in radiation oncology.
2. Geographic and Technology Expansion in International Markets
The company’s international footprint, particularly in Latin America, is expanding with improved Gamma Knife procedure volumes and technological upgrades such as the Esprit system in Peru. The upcoming Gamma Knife upgrade in Guadalajara, Mexico, with Hospital San Javier, exemplifies AMS’s strategy to deepen presence in established clinical markets leveraging strong local partnerships.
3. Utilization and Operational Efficiency as Value Drivers
Increasing patient throughput and utilization across treatment centers remains AMS’s core operational focus. This approach aims to leverage operating leverage inherent in radiation oncology centers, translating volume growth into improved margins and cash flow.
4. Capital Structure Optimization and Liquidity Management
Following the Third Amendment to its credit agreement and a $2 million subordinated financing from an entity controlled by the Executive Chairman, AMS has enhanced its financial flexibility. These actions provide a runway to pursue strategic alternatives while continuing operational execution and growth initiatives.
5. Long-Term Growth Through Certificate of Need Projects
AMS is advancing development opportunities in Rhode Island, including new radiation therapy and proton beam centers approved through certificates of need. These projects represent important growth catalysts in a core market with established health system partnerships.
Key Considerations
AMS’s Q2 performance reflects a business in transition, balancing growth initiatives with near-term financial discipline.
- Revenue Mix Shift: The growing share of Direct Patient Services revenue signals a move toward more controllable, recurring revenue streams.
- Credit Losses Impact: The $909,000 allowance for credit losses on older receivables highlights ongoing challenges in billing and collections, though management reports progress in accounts receivable systems.
- Capital Structure Constraints: The company’s need to amend credit agreements and pursue potential sale options underscores balance sheet pressures despite operational improvements.
- International Growth Potential: Success in Latin America, especially post-technology upgrades, supports AMS’s strategy to expand in emerging markets with high demand for advanced radiation therapies.
- Operating Cash Flow Strength: Robust cash generation underpins debt repayments and liquidity, providing a foundation for strategic flexibility.
Risks
AMS faces risks related to its capital structure, including the requirement to explore asset sales under its credit agreement amendments, which could impact long-term strategic autonomy. Additionally, credit loss exposures from insurance payors and the pace of reimbursement improvements remain potential headwinds. Competitive pressures in radiation oncology and regulatory uncertainties around reimbursement rates also pose ongoing challenges.
Forward Outlook
For the next quarter, AMS expects to continue growing patient volumes and revenue across its treatment platforms, with particular emphasis on expanding utilization in Rhode Island and international centers. Management anticipates maintaining strong operating cash flow and leveraging recent financing flexibility to support growth initiatives.
- Continued revenue growth driven by Direct Patient Services and PBRT activity.
- Focus on operational efficiency to improve margins and cash flow conversion.
For full-year 2026, AMS maintains its commitment to expanding its installed base of advanced radiation therapy technologies, increasing patient access, and strengthening its balance sheet while pursuing strategic alternatives to optimize capital structure.
Takeaways
AMS’s second quarter results demonstrate tangible progress in its strategic pivot toward a diversified radiation oncology platform with a growing emphasis on direct patient care and international expansion. The company’s ability to increase utilization and patient volumes across multiple geographies is a critical lever for future profitability and cash flow growth. While balance sheet constraints and credit loss provisions temper near-term earnings, recent financing arrangements provide necessary flexibility to pursue growth and capital structure optimization. Investors should monitor AMS’s execution on its Rhode Island development projects and international expansion as key indicators of sustained momentum.
- Strategic Execution: The shift to direct patient services and international growth is delivering revenue diversification and operational leverage.
- Financial Discipline: Strong operating cash flow and financing amendments enhance liquidity amid credit challenges.
- Growth Catalysts: Development projects in Rhode Island and technology upgrades in Latin America underpin long-term value creation.
Conclusion
American Shared Hospital Services is capitalizing on its strategic investments in advanced radiation therapy to drive meaningful revenue growth and operational improvements. Despite near-term financial headwinds from credit losses and legal expenses, the company’s expanding patient services footprint and improved cash flow generation provide a solid foundation for long-term shareholder value.
Industry Read-Through
AMS’s results highlight broader radiation oncology industry trends, including increasing demand for precision cancer treatments and the importance of diversified service offerings beyond equipment leasing. The company’s success in international markets, particularly Latin America, signals growth opportunities for peers willing to invest in technology upgrades and local partnerships. Additionally, AMS’s experience underscores the critical role of utilization optimization and operational efficiency in driving profitability in capital-intensive oncology services. The balance sheet challenges and financing complexities faced by AMS also reflect common industry dynamics as companies navigate investment cycles and evolving reimbursement environments.